Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its ...

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...